1-20 of 36
Aafia Chaudhry
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phased variant circulating tumor DNA (ctDNA) tracking provides limited additional power in predicting progressive disease compared with duplex variant tracking in patients with Relapsed/Refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) treated with odronextamab

Free
Jon Arnason, Won Seog Kim, David Tucker, Sabarish Ayyappan, Wei-Yi Cheng, Weiwei Tao, Namita Gupta, Hesham Mohamed, Aafia Chaudhry, Jurriaan Brouwer-Visser
Journal: Blood
Blood (2025) 146 (Supplement 1): 5309.
https://doi.org/10.1182/blood-2025-5309
Published: 2025
Journal Articles

Odronextamab plus chemotherapy in patients with previously untreated follicular lymphoma: First results from part 1 of the Phase 3 Olympia-2 study

Free
Kitsada Wudhikarn, Tuba Hacibekiroglu, Jose Angel Hernandez Rivas, Sebastian Grosicki, Jingxian Cai, Jingxiao Chen, Jurriaan Brouwer-Visser, Julia Held, Aafia Chaudhry, Hesham Mohamed, Ashish Risal, Aránzazu Alonso Alonso
Journal: Blood
Blood (2025) 146 (Supplement 1): 3600.
https://doi.org/10.1182/blood-2025-3600
Published: 2025
Journal Articles

Efficacy and safety of long-term odronextamab treatment in patients with relapsed/refractory follicular lymphoma: 3-year follow-up from the Phase 2 ELM-2 study

Free
Jose Villasboas Bisneto, Deepa Jagadeesh, Don Stevens, Michal Taszner, Jingxian Cai, Amulya Uppala, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Manjusha Namuduri, Geoffrey Chong
Journal: Blood
Blood (2025) 146 (Supplement 1): 3588.
https://doi.org/10.1182/blood-2025-3588
Published: 2025
Journal Articles

Odronextamab plus chemotherapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): First Results from part 1 of the Phase 3 Olympia-3 study

Free
Jean-Marie Michot, Munci Yagci, Katherine Kargus, Hesham Mohamed, Jingxiao Chen, Jurriaan Brouwer-Visser, Aafia Chaudhry, Nazia Iqbal, Matthew Matasar
Journal: Blood
Blood (2025) 146 (Supplement 1): 65.
https://doi.org/10.1182/blood-2025-65
Published: 2025
Journal Articles

Odronextamab (Odro) plus lenalidomide (+Len) in patients with relapsed/refractory (R/R) follicular lymphoma (FL): First results from part 1 (safety lead-in) of the Phase 3 OLYMPIA-5 study

Free
Umberto Vitolo, Lalita Norasetthada, Jae-Cheol Jo, Biyi Shen, Dina Flink, Min Zhu, Soujanya Chandrasekharan, Jingxiao Chen, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Sabela Bobillo-Varela, Catherine Thieblemont
Journal: Blood
Blood (2025) 146 (Supplement 1): 5381.
https://doi.org/10.1182/blood-2025-5381
Published: 2025
Journal Articles

Odronextamab treatment for patients with rare subtypes of relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL): Updated efficacy and safety analyses from a dedicated cohort of the ELM-2 study

Free
Mary-Margaret Keating, Tae Min Kim, Farrukh Awan, Jingxian Cai, Amulya Uppala, Aafia Chaudhry, Hesham Mohamed, Manjusha Namuduri, Jan Walewski
Journal: Blood
Blood (2025) 146 (Supplement 1): 5523.
https://doi.org/10.1182/blood-2025-5523
Published: 2025
Journal Articles

Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study

Open Access
Clinical Trials & Observations
Max S. Topp, Matthew Matasar, John N. Allan, Stephen M. Ansell, Jeffrey A. Barnes, Jon E. Arnason, Jean-Marie Michot, Neta Goldschmidt, Susan M. O’Brien, Uri Abadi, Irit Avivi, Yuan Cheng, Dina M. Flink, Min Zhu, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, Jennifer L. Crombie
Journal: Blood
Blood (2025) 145 (14): 1498–1509.
https://doi.org/10.1182/blood.2024027044
Published: 2025
Includes: Supplemental data
Journal Articles

Evaluation of CAR-Hematotox Scoring As a Predictor of Infection Risk Following Treatment with Odronextamab (a CD20×CD3 Bispecific Antibody) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Free
Matthew Matasar, David Tucker, Tae Min Kim, Stefano Luminari, Yuan Cheng, Jingjin Li, Saleem Shariff, Hesham Mohamed, Srikanth Ambati, Aafia Chaudhry
Journal: Blood
Blood (2024) 144 (Supplement 1): 3076.
https://doi.org/10.1182/blood-2024-200259
Published: 2024
Journal Articles

Efficacy and Safety of Odronextamab in Rare Subtypes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL): Data from a Dedicated Cohort of Other B-NHLs in the ELM-2 Study

Free
Emmanuel Bachy, Tae Min Kim, Shang-Ju Wu, Jan Walewski, Jingxian Cai, Nickolas Sophos, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, H. Miles Prince
Journal: Blood
Blood (2024) 144 (Supplement 1): 4502.
https://doi.org/10.1182/blood-2024-200150
Published: 2024
Journal Articles

Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study

Free
Elizabeth Brem, Wojciech Jurczak, David Belada, Jaime Perez de Oteyza, Aranzazu Alonso Alonso, Fevzi Altuntas, Michał Kwiatek, Joshua Brody, Ernesto Perez Persona, Mustafa Yenerel, Monica Tani, Jingxian Cai, Priya Deshpande, Saleem Shariff, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, Ashish Risal, Ruemu Birhiray
Journal: Blood
Blood (2024) 144 (Supplement 1): 4411.
https://doi.org/10.1182/blood-2024-200080
Published: 2024
Journal Articles

Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 Studies

Free
John N. Allan, Jennifer L. Crombie, Matthew Matasar, Max S. Topp, Jan Walewski, Tae Min Kim, Won-Seog Kim, Yuan Cheng, Dina Flink, Bertha Fearon Chalet, Hesham Mohamed, Srikanth Ambati, Aafia Chaudhry, Jon E. Arnason
Journal: Blood
Blood (2024) 144 (Supplement 1): 3118.
https://doi.org/10.1182/blood-2024-199980
Published: 2024
Journal Articles

Treatment Duration and Risk of Fatal Infections in Patients with B-Cell Non-Hodgkin Lymphoma Achieving Complete Response with Odronextamab

Free
Gottfried von Keudell, Eliza A. Hawkes, Cecilia Carpio, Max S. Topp, Biyi Shen, Jingjin Li, Claire Hearnden, Saleem Shariff, Hesham Mohamed, Srikanth Ambati, Aafia Chaudhry, Sabarish Ayyappan
Journal: Blood
Blood (2024) 144 (Supplement 1): 3080.
https://doi.org/10.1182/blood-2024-200623
Published: 2024
Journal Articles

Matching-Adjusted Indirect Comparisons (MAICs) of Odronextamab Versus Mosunetuzumab and Epcoritamab for the Treatment of Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) after Two or More Lines of Systemic Therapy

Free
Deepa Jagadeesh, Silvana Novelli, Stefano Luminari, Michal Taszner, Michele Merli, Yingzxin Xu, Siddhesh Kamat, Liza Mastikhina, Srikanth Ambati, Jenny Chen, Keith Chan, Shannon Cope, Sam Keeping, Clyde Caisip, Hesham Mohamed, Aafia Chaudhry, James Harnett, Jose C. Villasboas Bisneto
Journal: Blood
Blood (2024) 144 (Supplement 1): 7803.
https://doi.org/10.1182/blood-2024-200865
Published: 2024
Journal Articles

Evaluation of Baseline CAR-Hematotox Scores to Predict Increased Severe Infection Risk in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Odronextamab

Free
Matthew Matasar, David Tucker, Tae Min Kim, Stefano Luminari, Yuan Cheng, Jingjin Li, Saleem Shariff, Hesham Mohamed, Srikanth Ambati, Aafia Chaudhry
Journal: Blood
Blood (2024) 144 (Supplement 1): 1650.
https://doi.org/10.1182/blood-2024-200166
Published: 2024
Journal Articles

Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study

Free
Matthew Matasar, Max S. Topp, John N. Allan, Stephen M. Ansell, Jeffrey A. Barnes, Jon E. Arnason, Jean-Marie Michot, Neta Goldschmidt, Susan M. O'Brien, Uri Abadi, Irit Avivi Mazza, Jingxian Cai, Julia Zecchini, Min Zhu, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, Jennifer L. Crombie
Journal: Blood
Blood (2024) 144 (Supplement 1): 866.
https://doi.org/10.1182/blood-2024-199155
Published: 2024
Journal Articles

Efficacy and Safety of Odronextamab in Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL): Data from the R/R MZL Cohort in the ELM-2 Study

Free
Tae Min Kim, Seok-Goo Cho, Michal Taszner, Geoffrey Chong, Jingxian Cai, Amulya Uppala, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, John N. Allan
Journal: Blood
Blood (2024) 144 (Supplement 1): 862.
https://doi.org/10.1182/blood-2024-200190
Published: 2024
Journal Articles

Odronextamab Monotherapy for the Treatment of Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Focus on Clinical Pharmacology and Pharmacometrics in the ELM-1 and ELM-2 Studies

Free
Min Zhu, Daniela Conrado, Kamal Srinivasan, Jurriaan Brouwer-Visser, Hong Yan, Hesham Mohamed, Aafia Chaudhry, Srikanth Ambati, Lutz Harnisch, John D Davis
Journal: Blood
Blood (2023) 142 (Supplement 1): 1436.
https://doi.org/10.1182/blood-2023-180675
Published: 2023
Journal Articles

Circulating Tumor DNA Analysis Associates with Progression-Free Survival (PFS) with Odronextamab Monotherapy in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Identification of Minimal Residual Disease Status and High-Risk Subgroups from the Phase 2 ELM-2 Study

Free
Jon E. Arnason, Jurriaan Brouwer-Visser, Stefano Luminari, David Tucker, Tae Min Kim, Won Seog Kim, Laura Magnano, Dylan Sun, Jessica Cai, Kamil Cygan, Srikanth Ambati, Hesham Mohamed, Aafia Chaudhry, Vladimir Jankovic
Journal: Blood
Blood (2023) 142 (Supplement 1): 427.
https://doi.org/10.1182/blood-2023-179812
Published: 2023
Journal Articles

Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study

Free
Elzbieta Iskierka-Jazdzewska, Won Seog Kim, Seok-Goo Cho, Tae Min Kim, Isidro Jarque, Tadeusz Robak, Michelle Poon, H. Miles Prince, Sung Yong Oh, Francesca Lim, Cecilia Carpio, Tran-Der Tan, Sabarish Ayyappan, Antonio Gutiérrez, Huilai Zhang, Junning Cao, Mingzhi Zhang, Benoit Tessoulin, Jingjin Li, Cristina Ivanescu, Matthew Reaney, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, James Harnett, Lei Chi, Jan Walewski
Journal: Blood
Blood (2023) 142 (Supplement 1): 4504.
https://doi.org/10.1182/blood-2023-180743
Published: 2023
Journal Articles

Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up

Free
Jose. C. Villasboas, Tae Min Kim, Michal Taszner, Silvana Novelli, Seok-Goo Cho, Michele Merli, Ana Jimenez Ubieto, Benoit Tessoulin, Michelle Poon, Jan Walewski, Shuhua Yi, Yuqin Song, Geoffrey Chong, Stefano Luminari, Emmanuel Bachy, Stephanie Guidez, Aranzazu Alonso, Deepa Jagadeesh, Wei Zhang, Laura Magnano, Elżbieta Iskierka-Jażdżewska, Monica Tani, Jessica Cai, Amulya Uppala, Saleem Shariff, Lei Chi, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, David Tucker
Journal: Blood
Blood (2023) 142 (Supplement 1): 3041.
https://doi.org/10.1182/blood-2023-181650
Published: 2023